Analysts Set Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Price Target at $19.50

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) has earned an average recommendation of “Buy” from the six brokerages that are covering the stock, Marketbeat reports. Six investment analysts have rated the stock with a buy rating. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $19.50.

Several equities analysts have issued reports on the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zevra Therapeutics in a report on Monday, April 1st. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price target on shares of Zevra Therapeutics in a research report on Wednesday, April 3rd. Maxim Group boosted their price objective on Zevra Therapeutics from $12.00 to $18.00 and gave the company a “buy” rating in a research note on Tuesday, April 2nd. Finally, William Blair restated an “outperform” rating on shares of Zevra Therapeutics in a research report on Tuesday, March 12th.

Hedge Funds Weigh In On Zevra Therapeutics

Institutional investors have recently bought and sold shares of the company. International Assets Investment Management LLC boosted its position in shares of Zevra Therapeutics by 555.0% during the 4th quarter. International Assets Investment Management LLC now owns 6,550 shares of the company’s stock worth $43,000 after purchasing an additional 5,550 shares in the last quarter. VisionPoint Advisory Group LLC purchased a new position in shares of Zevra Therapeutics during the 3rd quarter worth approximately $33,000. Strs Ohio acquired a new position in shares of Zevra Therapeutics during the 3rd quarter worth approximately $37,000. Tower Research Capital LLC TRC grew its holdings in Zevra Therapeutics by 134.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 9,673 shares of the company’s stock valued at $63,000 after buying an additional 5,545 shares during the last quarter. Finally, Commonwealth Equity Services LLC purchased a new position in Zevra Therapeutics during the third quarter worth $52,000. 35.03% of the stock is owned by institutional investors and hedge funds.

Zevra Therapeutics Stock Performance

Shares of ZVRA opened at $4.81 on Wednesday. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 0.08. Zevra Therapeutics has a 52-week low of $3.89 and a 52-week high of $7.28. The stock has a 50 day moving average price of $5.46 and a 200 day moving average price of $5.36. The company has a market capitalization of $208.90 million, a price-to-earnings ratio of -3.73 and a beta of 1.87.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its earnings results on Thursday, March 28th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.20). Zevra Therapeutics had a negative net margin of 167.69% and a negative return on equity of 68.41%. The company had revenue of $13.22 million during the quarter, compared to analyst estimates of $13.35 million. Research analysts predict that Zevra Therapeutics will post -1.65 EPS for the current fiscal year.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.